Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Operating Leases (2020 - 2025)

Maxcyte (MXCT) has disclosed Operating Leases for 6 consecutive years, with $16.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 3.98% to $16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Dec 2025, down 3.98% year-over-year, with the annual reading at $16.5 million for FY2025, 3.98% down from the prior year.
  • Operating Leases for Q4 2025 was $16.5 million at Maxcyte, down from $16.8 million in the prior quarter.
  • The five-year high for Operating Leases was $18.0 million in Q4 2023, with the low at $500200.0 in Q3 2021.
  • Average Operating Leases over 5 years is $14.0 million, with a median of $15.9 million recorded in 2022.
  • The sharpest move saw Operating Leases surged 2873.17% in 2022, then decreased 4.45% in 2024.
  • Over 5 years, Operating Leases stood at $5.2 million in 2021, then soared by 209.18% to $15.9 million in 2022, then increased by 12.74% to $18.0 million in 2023, then dropped by 4.45% to $17.2 million in 2024, then dropped by 3.98% to $16.5 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $16.5 million, $16.8 million, and $17.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.